Company research / URGN
UroGen Pharma Ltd. (URGN)
- Sector Manufacturing
- Incorporated L3
- Fiscal year ends Dec 31
For the year ended 2025-12-31, UroGen Pharma Ltd. reported revenue of $109.79M. Revenue grew 21.4% from the prior annual period.
Key ratios (year ended 2025-12-31)
88.7%
Gross margin
-113.7%
Operating margin
-139.8%
Net margin
21.4%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.